Since intensified fed-batch could rival the cell-specifc productivity of a conventional fed-batch, we developed novel hybrid strategies to either allow for acceptable seeding densities without compromising productivity, or alternatively, to push the productivity the furthest in order to reduce timelines. We have evaluated a more cell-intensive approach to both cell line adaptation and production culture as a means of achieving high integrated viable cell density (IVCD) in order to improve cell culture process yields. rfab was produced at a significant level achieving 1. 7 a) while maintaining a lactate concentration below 2.0 g/l with ammonium utilized toward end of the culture (fig. Both strategies improved titer by 100% in 14 days relative to the standard fed-batch process with moderate and acceptable changes in product quality attributes. the 5 l bioreactor growth pattern mimicked that observed in the small-scale doe study for bioreactor 8 achieving an ivcd of 86.5 × 10 6 cells × day/ml at day 16 (fig. Yet, as intensified fed-batch may not always be possible due to limited facility operational mode, we also separately increased the q p with the addition of specifc media additives. To do so, we worked separately on the increase of the IVCD as high seeding fed-batch capacity. (e.g., IVCD, Qp, consumption rates) and multi-parametric assessment of any type of time-series. and tyrosine on integral viable cell density (IVCD), harvest cell viability. Leveraging these factors along with other cell culture. The nutrient level in perfusion cultures can be controlled at two levels. While titer is influenced by the biomass (expressed as IVCD), the culture time and the cell-specifc productivity (q p), we changed independently each of these parameters to tune our process strategy towards adapted solutions to individual manufacturing needs. Cell culture intermediate retains obtained from a commercial production. The slope of an IVCD-graph allows deeper insight into the cellular performance and expresses common cell culture parameters including cell-specific growth (), -productivity (qP), -glucose consumption (qGluc) and lactate production (qLac). All manufacturing approaches tend to follow the generally accepted dogma of increasing titer since it directly increases manufacturing output. In the field of therapeutic antibody production, diversification of fed-batch strategies is flourishing in response to the market demand.

Ivcd cell culture